Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research ...

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating ...

Biocon wins Health Canada approval for Yesintek autoinjector, expanding autoimmune biosimilar options in Canada. Read more.

In Biocon’s continuing effort to divest and Eris Lifesciences’ attempt to grow, the companies have expanded a previous agreement, with Bangalore-based generics giant Biocon selling Indian branded ...

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a ...

Biocon also reported a 23% year-on-year decline in interest costs to ₹213 crore after measures to strengthen its balance ...

Last month, Biocon's Malaysia unit also received the European Medicines Agency's (EMA) approval for a new drug product fill ...

With the stock currently trading at Rs 435.45, Biocon continues to be an active player in the Nifty Midcap 150 index.

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon Q1 profit surged 348% to Rs. 141 crore as revenue rose 10% to Rs. 4,336 crore. Biosimilars and generics led growth, ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...